![Jeffrey Rudy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Rudy
Profile
Jeffrey J.
Rudy worked as a Principal at Agouron Pharmaceuticals LLC, Amgen, Inc., Cell Genesys, Inc., Gilead Sciences, Inc., and Pfizer Inc. He also worked as a Vice President-Clinical Operations at Celladon Corp., Anaborex, Inc., and Capricor Therapeutics, Inc. Prior to his career in the pharmaceutical industry, he obtained an undergraduate degree from The Ohio State University.
Former positions of Jeffrey Rudy
Companies | Position | End |
---|---|---|
CAPRICOR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - |
AMGEN INC. | Corporate Officer/Principal | - |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Agouron Pharmaceuticals LLC
![]() Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Jeffrey Rudy
The Ohio State University | Undergraduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 4 |
---|---|
PFIZER, INC. | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
AMGEN INC. | Health Technology |
CAPRICOR THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
Anaborex, Inc.
![]() Anaborex, Inc. Medical/Nursing ServicesHealth Services Anaborex, Inc. provides clinical research services for metabolic diseases. The company develops drugs for the treatment of cancer related wasting syndrome. It was founded in 2005 by Alan Saven and Jorge Nieva and is located in La Jolla, CA | Health Services |
Celladon Corp.
![]() Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Agouron Pharmaceuticals LLC
![]() Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Rudy